摘要
目的观察多西紫杉醇加表柔比星、环磷酰胺(TEC方案)新辅助化疗治疗局部晚期乳腺癌(LABC)疗效及毒副反应.方法收治28例LABC患者,Ⅲa期18例,Ⅲb期10例,中位年龄45岁.化疗剂量为多西紫杉醇75mg/m^2静滴、表柔比星60mg/m^2和环磷酰胺500mg/m^2静推,每3周为1个周期.在2个周期后评价疗效并决定是否继续予1~2个周期TEC方案后再接受手术或放疗.结果28例患者接受2~4个周期TEC方案的新辅助化疗,病理完全缓解率、临床完全缓解率及临床部分缓解率分别为14.3%、21.4%、53.6%.本组的手术切除率为89.3%.Ⅲ~Ⅳ度白细胞减少的发生率分别占总周期数的11.9%和14.2%,3例患者出现白细胞减少性发热.常见非血液系统不良反应为轻中度脱发、恶心、呕吐、体液储留、肌肉关节疼痛等.结论多西紫杉醇联合表柔比星、环磷酰胺是LABC的一种安全有效的新辅助化疗方案.
Objective To investigate the clinical response and safety of new adjuvant chemotherapy with docetaxel, epirubicin (E) and cytoxan (C) for localy advanced breast cancer (LABC). Methods 28 women with LABC were treated, mediums age was 45.18 patients had clinical stage Ⅲa disease, 10 had stage Ⅲb disease. The dose was: docetaxel (T) 75 mg/m^2, epirubicin (E) 60 mg/m^2, cytoxan (C) 500 mg/m^2 every 3 weeks. After 2 - 4 cycles of TEC, a pilot clinical response evaluation was performed by investigators for each patient to decide whether she should receive another 1 - 2 cycles of TEC before surgery or radiation therapy. Results 28 patients received 2 -4 cycles of TEC regimen. The pathological complete response (PCR), clinical complete response (CCR) and clinical partial response (CPR) rates were 14.3%, 21.4% and 53. 6% respectively. Tumor operation rates were 92. 8 % in this group. Incidence of Ⅲ - Ⅳ Grade neutropenia was 11.9% and 14. 2% of cycles, and 2 patients suffered from neutropenia with fever. Non -hematological adverse events were alopecia, nausea, vomiting, fluid retention, myalgia and arthralgia, which were mild tomoderate. Conclusion Neoadjuvant chemotherapy with docetaxel and epirubicin plus cytoxan is effective and well tolerated by women with locally advanced breast cancer.
出处
《昆明医学院学报》
2006年第5期99-102,共4页
Journal of Kunming Medical College